Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04541225
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:04.317929+00:00
Published At
2023-07-14T00:00:00+00:00
Record Updated At
2023-07-14
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Glioma", "Glioma, Malignant", "Glioma, Mixed", "Glial Cell Tumors", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor", "Malignant Tumor of Breast", "Advanced Breast Cancer", "Advanced Breast Carcinoma", "Metastatic Breast Cancer", "Metastatic Breast Carcinoma", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration-resistant Prostate Cancer", "Castration Resistant Prostatic Neoplasms", "Glioblastoma", "Recurrent Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-07-14"
protocolSection.identificationModule.nctId
"NCT04541225"
protocolSection.identificationModule.officialTitle
"Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Glioma (protocolSection.conditionsModule.conditions)
  • Glioma, Malignant (protocolSection.conditionsModule.conditions)
  • Glioma, Mixed (protocolSection.conditionsModule.conditions)
  • Glial Cell Tumors (protocolSection.conditionsModule.conditions)
  • Breast Cancer (protocolSection.conditionsModule.conditions)
  • Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Cancer of Breast (protocolSection.conditionsModule.conditions)
  • Cancer of the Breast (protocolSection.conditionsModule.conditions)
  • Breast Tumor (protocolSection.conditionsModule.conditions)
  • Malignant Tumor of Breast (protocolSection.conditionsModule.conditions)
  • Advanced Breast Cancer (protocolSection.conditionsModule.conditions)
  • Advanced Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Prostatic Cancer (protocolSection.conditionsModule.conditions)
  • Cancer of Prostate (protocolSection.conditionsModule.conditions)
  • Cancer of the Prostate (protocolSection.conditionsModule.conditions)
  • Prostate Neoplasm (protocolSection.conditionsModule.conditions)
  • Castrate Resistant Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Castration-resistant Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Castration Resistant Prostatic Neoplasms (protocolSection.conditionsModule.conditions)
  • Glioblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Glioblastoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.